Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting-Reference-Cited by-同舟云学术

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting

Published:2003-05-29 Issue:12 Volume:97 Page:3090-3098
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Poli-Bigelli Sergio,Rodrigues-Pereira Jose,Carides Alexandra D.,Julie Ma Guoguang,Eldridge Krista,Hipple Anita,Evans Judith K.,Horgan Kevin J.,Lawson Francesca,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists

2. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

3. The Changeable Nature of Patients' Fears Regarding Chemotherapy

4. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference

5. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

Cited by 490 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research trends on chemotherapy induced nausea and vomiting: a bibliometric analysis;Frontiers in Pharmacology;2024-09-13

2. Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database;Frontiers in Pharmacology;2024-07-31

3. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study;Thoracic Cancer;2024-07-29

4. Real hopes in antiemetic therapy;Meditsinskiy sovet = Medical Council;2024-07-25

5. Bibliometric and visual analysis of chemotherapy-induced nausea and vomiting (2004-2023);Frontiers in Oncology;2024-04-24